Referral for Radioactive Iodine Therapy in Hyperthyroidism

Primary Indications for RAI Referral

• Referral for RAI therapy in hyperthyroidism should be considered for patients with persistent or recurrent Graves' disease after antithyroid drug therapy, toxic nodular goiter, or when antithyroid drugs are contraindicated or refused, with the goal of achieving definitive treatment through permanent hypothyroidism, as recommended by the American College of Physicians, based on evidence from the Annals of Internal Medicine 1
• Patients with TSH levels that are undetectable or <0.1 mIU/L, particularly those with overt Graves' disease or nodular thyroid disease, are appropriate candidates for definitive therapy, according to the American College of Physicians, based on evidence from the Annals of Internal Medicine 1
• Treatment is typically not recommended for patients with TSH levels between 0.1 and 0.45 mIU/L or when thyroiditis is the cause, as these conditions may be transient, as stated by the American College of Physicians, based on evidence from the Annals of Internal Medicine 1
• Patients with toxic nodular goiter requiring definitive treatment should be referred for RAI therapy, as recommended by the American College of Physicians, based on evidence from the Annals of Internal Medicine 1
• Patients who cannot tolerate or refuse antithyroid medications due to side effects or contraindications should be referred for RAI therapy, as recommended by the American College of Physicians, based on evidence from the Annals of Internal Medicine 1
• Patients with persistent hyperthyroidism after 6 weeks despite medical management may warrant endocrine consultation for RAI consideration, according to the American Society of Clinical Oncology, based on evidence from the Journal of Clinical Oncology 2

Contraindications and Special Circumstances

• Pregnancy is an absolute contraindication to RAI therapy, as stated by the American College of Physicians, based on evidence from the Annals of Internal Medicine 1
• Patients with thyroiditis as the underlying cause should not receive RAI, as this condition is typically self-limited and resolves with supportive care, according to the American Society of Clinical Oncology and the American College of Physicians, based on evidence from the Journal of Clinical Oncology and the Annals of Internal Medicine 1, 2
• TSH levels between 0.1-0.45 mIU/L without cardiac disease or atrial fibrillation can be monitored at 3-12 month intervals rather than immediately referred, as recommended by the American Medical Association, based on evidence from JAMA 3
• Patients with immune checkpoint inhibitor-induced thyrotoxicosis (Grade 1-2) should be managed with beta-blockers and supportive care, not RAI, according to the American Society of Clinical Oncology, based on evidence from the Journal of Clinical Oncology 2

Special Populations

• Patients with atrial fibrillation, cardiac disease, or severe symptoms (Grade 3-4) require urgent endocrine consultation and may need hospitalization, as recommended by the American Society of Clinical Oncology and the American Medical Association, based on evidence from the Journal of Clinical Oncology and JAMA 2, 3
• Older patients with cardiac complications should be referred promptly, as they are at higher risk for cardiovascular morbidity, according to the American Medical Association, based on evidence from JAMA 3
• Patients with known nodular thyroid disease exposed to excess iodine (e.g., radiographic contrast) may develop overt hyperthyroidism and require special consideration, as stated by the American Medical Association, based on evidence from JAMA 3